Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Review

(2562) Views  (600) Full article downloads

Authors: Zinelabidine Abouelfadel, E David Crawford

Published Date April 2008 Volume 2008:4(2) Pages 513 - 526

DOI: http://dx.doi.org/10.2147/TCRM.S6863

Zinelabidine Abouelfadel^1,2, E David Crawford¹

¹Urologic Oncology, University of Colorado Cancer Center, Aurora, CO, USA; ²Currently, Amiri Hospital Kuwait University, Urology Section, Kuwait City

Abstract: Hormone therapy is well established for treating patients with prostate cancer and remains the mainstay of the treatment of metastatic and locally advanced disease, this article reviews the rationale for its use, its different forms, and complications and controversies still surrounding some of its modalities. Availability of long-acting synthetic luteinizing hormone-releasing hormone (LHRH) agonists revolutionized the hormonal treatment of prostate cancer, and helped to avoid the emotional and psychological effects related to surgical castration. The depot formula has gained wide acceptance from both patients and physicians. This review emphasizes the newer, long-acting formula, leuprorelin (leuprolide acetate), especially the 6-month formula, its advantage over over shorter-acting depot products, and its potential to become a standard of care for patients eligible for androgen deprivation therapy.

Keywords: prostate cancer, androgen deprivation therapy (adt), leuprorelin

Readers of this article also read: